| Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. | |
| | |
MedLine Citation:
|
PMID: 21812509 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Dexmedetomidine (Precedex®), a pharmacologically active dextroisomer of medetomidine, is a selective α(2)-adrenergic receptor agonist. It is indicated in the US for the sedation of mechanically ventilated adult patients in an intensive care setting and in non-intubated adult patients prior to and/or during surgical and other procedures. This article reviews the pharmacological properties, therapeutic efficacy and tolerability of dexmedetomidine in randomized, double-blind, placebo-controlled, multicentre studies in these indications. Post-surgical patients in an intensive care setting receiving dexmedetomidine required less rescue sedation with intravenous propofol or intravenous midazolam to achieve and/or maintain optimal sedation during the assisted ventilation period than placebo recipients, according to two randomized, double-blind, multinational studies. Moreover, significantly more dexmedetomidine than placebo recipients acquired and/or maintained optimal sedation without rescue sedation. Sedation with dexmedetomidine was also effective in terms of the total dose of morphine administered, with dexmedetomidine recipients requiring less morphine than placebo recipients; with regard to patient management, dexmedetomidine recipients were calmer and easier to arouse and manage than placebo recipients. Intravenous dexmedetomidine was effective as a primary sedative in two randomized, double-blind, placebo-controlled, multicentre studies in adult patients undergoing awake fibre-optic intubation or a variety of diagnostic or surgical procedures requiring monitored anaesthesia care. In one study, significantly fewer dexmedetomidine than placebo recipients required rescue sedation with intravenous midazolam to achieve and/or maintain optimal sedation; conversely, in another study, rescue sedation with intravenous midazolam was not required by significantly more dexmedetomidine than placebo recipients. Primary sedation with intravenous dexmedetomidine was also effective in terms of the secondary efficacy endpoints, including the mean total dose of midazolam and fentanyl administered and the percentage of patients requiring further sedation (in addition to dexmedetomidine or placebo and midazolam), with, for the most part, significant between-group differences observed in favour of dexmedetomidine over placebo. In general, no significant differences were observed between the dexmedetomidine and placebo treatment groups in the anaesthesiologists' assessment of ease of intubation, haemodynamic stability, patient cooperation and/or respiratory stability. Intravenous dexmedetomidine is generally well tolerated when utilized in mechanically ventilated patients in an intensive care setting and for procedural sedation in non-intubated patients. Dexmedetomidine is associated with a lower rate of postoperative delirium than midazolam or propofol; it is not associated with respiratory depression. While dexmedetomidine is associated with hypotension and bradycardia, both usually resolve without intervention. Thus, intravenous dexmedetomidine provides a further option as a short-term (<24 hours) primary sedative in mechanically ventilated adult patients in an intensive care setting and in non-intubated adult patients prior to and/or during surgical and other procedures. |
| | |
Authors:
|
Sheridan M Hoy; Gillian M Keating |
Related Documents
:
|
16049529 - Intraocular pressure control and persistence on treatment in glaucoma and ocular hypert... 15022259 - Comparison of single and multiple applications of gaalas laser on rat medial collateral... 21659789 - Magical thinking in somatoform disorders: an exploratory study among patients with susp... 22159879 - Remifentanil use for cesarean section in a patient with intracranial re-ruptured arteri... 16673139 - The end of submacular surgery for age-related macular degeneration? a meta-analysis. 22223819 - A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patien... 8259869 - Continuous nebulised salbutamol and oral once a day prednisolone in status asthmaticus. 8151609 - Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to... 21687579 - An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Drugs Volume: 71 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-08-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 1481-501 Citation Subset: IM |
Affiliation:
|
Adis, a Wolters Kluwer Business, Auckland, New Zealand. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Romidepsin: in the treatment of T-cell lymphoma.
Next Document: Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy.